NCT06395103

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

← Hub

Registry fields

Overall status: RECRUITING
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Study type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Primary purpose: TREATMENT
Intervention type: BIOLOGICAL
Interventions: Zilovertamab vedotin
Lead sponsor: Merck Sharp & Dohme LLC (INDUSTRY)

Cached at: 2026-07-28 02:39:06

View on ClinicalTrials.gov

Brief summary

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report